Lowest Price Guaranteed From USD 5,899
Published
January 2021
Pages
483
View Count
8101
Example Insights
-thumb.PNG) |
 |
 |
-thumb.PNG) |
 |
-thumb.PNG) |
 |
 |
 |
 |
Report Description
Over the years, the biopharmaceutical market has grown into a promising, high value vertical within the overall pharmaceutical industry. In fact, nearly 29% and 25% of the total number of novel drugs approved by the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) in 2018 and 2019, respectively, were biologics. As a result, the pipeline of biologics and biosimilars is growing at a commendable pace. Given that the development and manufacturing of such therapies require living biological systems, there has been a surge in demand for different types of cell lines. In fact, around 84% of the therapeutic proteins marketed in the last five years, were produced using various mammalian and microbial cells. A recent study revealed that over 30,000 research articles published in 33,000 journals featured data generated from experiments that used misidentified or contaminated cell lines. This is a genuine concern in the field of medical research, which is becoming increasingly dependent on cell-based assays and experimentation. Therefore, in modern medical research, proper cell line characterization is a necessity in order to preserve the authenticity and accuracy of experimental research.
Given the cost intensive nature of pharmacological R&D, medical researchers / drug developers are consistently on the lookout for ways to optimize operational efficiencies, as well as reduce affiliated costs; in this context, outsourcing has emerged as a preferred business model. Presently, there are several contact service providers that claim to have the necessary expertise to develop and characterize cell lines. The technical aspect of this field is also witnessing a lot of innovation, especially with regard to automating various steps of the cell line development process. New genome editing technologies, such as the CRISPR/Cas-9, are also being extensively used to improve the quality of recombinant cell lines. Unlike drug developers, the capabilities of service providers are usually more focused to their respective service portfolios. Moreover, such companies ensure that they have the latest upgrades in equipment and infrastructure, in order to improve the quality of services offered. In fact, in the recent past, a number of service providers offering cell lines-related services, have forged strategic alliances with and / or acquired other players, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, we believe the contract services market for cell line development and characterization is likely to evolve at a steady pace, till 2030.
The “Cell Line Development and Characterization Services Market (2nd Edition), 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry, over the next ten years. The study underlines an in-depth analysis of the services offered for the development and characterization of cell lines, which are intended for use in various R&D and / or therapeutic purposes. In addition to other elements, it includes:
One of the key objectives of the report was to estimate the existing market size and future growth opportunities for cell line development and characterization service providers. Based on multiple parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the biologics market, we have developed informed estimates on the financial evolution of the market over the period 2020-2030.
For cell line development services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial, insect and avian), [B] applications of cell lines (R&D operations and drug development), [C] company size (small, mid-sized and large) and key geographies (North America, Europe, Asia, Oceania and Rest of the World).
For cell line characterization services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial and others), [B] applications of cell lines (R&D operations and drug development), [C] type of service provider (industry players and non-industry players) and [D] key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM) and Rest of the World (RoW)).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders (in reverse chronological order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell line development and characterization services market in the mid to long term.
Chapter 3 provides a general introduction to cell cultures and cell lines, including details related to various types of cell lines, based on their sources of origin, and key characteristics, applications and concerns associated with their use in drug development and research. The chapter also elaborates the recombinant and hybridoma cell line development process workflow. Further, it outlines the general concepts of cell line characterization along with a detailed description of different types of testing methods used for such purposes. In addition, it also presents the advantages and associated risks related to outsourcing of cell line development and characterization operations. In this chapter, we have briefly discussed the most common services offered by the service providers, along with cell line development and characterization services.
Chapter 4 provides an overview of the overall cell line development services landscape. It includes information related to over 220 contract service providers that are currently active in this domain. It features an in-depth analyses of the market, information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free / animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy / regenerative medicine / tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical / protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines.
Chapter 5 provides an insightful competitiveness analysis of the cell line development service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems offered, availability of proprietary / licensed technology platform, type of gene expression and availability of additional cell line related services).
Chapter 6 features detailed profiles of some of the key players that are active in the cell line development domain. Each profile presents a brief overview of the company, its cell line development and complementary services portfolio, financial information (if available), recent developments and an informed future outlook.
Chapter 7 provides an overview of the overall cell line characterization services landscape. It includes information related to over 140 industry and non-industry contract service providers that are currently active in this domain. It features in-depth analyses of the market, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity / stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), types of cell line identity / stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting / profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral / adventitious agents contamination testing, retroviral contamination testing and rodent virus testing / in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations / certifications and overall turnaround time. For non-industry players, the report features additional information on number of STR loci amplified, type of genotyping kit used and service fee charged.
Chapter 8 provides an insightful competitiveness analysis of the cell line characterization service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (in terms of experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems handled and size of the service portfolio).
Chapter 9 features detailed profiles of some of the key players that are active in the cell line characterization domain. Each profile presents a brief overview of the company, its cell line characterization services portfolio, financial information (if available), recent developments and an informed future outlook.
Chapter 10 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in the cell line development and characterization market in the time period between 2015 and 2020 (till September). It includes a brief description of partnership models (such as technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, process development agreements, clinical trial agreements and other relevant deals) adopted by the stakeholders.
Chapter 11 features detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio.
Chapter 12 presents an elaborate discussion on the requirements defined by various regulatory authorities, across different regions, related to the characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.
Chapter 13 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line development services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines / expression systems (mammalian, microbial, insect and avian), applications of cell lines (R&D operations and drug development), company size (small, mid-sized and large) and key geographical regions (North America, Europe, Asia, Oceania and Rest of the World).
Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line characterization services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines (mammalian, microbial and others), applications of cell lines (R&D operations and drug development), type of player (industry and non-industry) and key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM), Rest of the World (RoW)).
Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Fai Poon (Founder and President, Quacell Biotechnology), Louis Boon (Chief Scientific Officer, Polpharma Biologics), Fan Chen (Former Vice President BioProcessing, LakePharma), Michael Pointek (Founder and Managing Director, ARTES Biotechnology), Nienke Smits (Client Relations Manager, Immunoprecise Antibodies) and Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics).
Chapter 16 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.
Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Key Questions Answered
1.3. Research Methodology
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cell Culture
3.2.1. Types of Cell Cultures by Origin
3.2.1.1. Primary Cell Cultures
3.2.1.2. Secondary Cell Cultures
3.2.2. Types of Cell Cultures by Growth Properties
3.2.2.1. Adherent Cell Cultures
3.2.2.2. Suspension Cell Cultures
3.2.3. Classification by Types of Cell Lines
3.2.3.1. Finite Cell Lines
3.2.3.2. Continuous Cell Lines
3.2.3.3. Recombinant Cell Lines
3.2.3.4. Hybridoma Cell Lines
3.3.4. Classification by Sources of Cell Lines
3.3.4.1. Mammalian Cell Lines
3.3.4.2. Non-Mammalian Cell Lines
3.5. Overview of Cell Line Development
3.5.1. Recombinant Cell Line Development
3.5.1.1. Vector Construction
3.5.1.2. Transgene Delivery into Host Cells
3.5.1.3. Cell Line Selection and Gene Amplification
3.5.1.4. Clone Selection
3.5.1.5. Stability Studies
3.6.2. Hybridoma Cell Line Development
3.7. Overview of Cell Line Characterization
3.7.1. Identity Testing
3.7.1.1. Karyotype Analysis
3.7.1.2. Isozyme Analysis
3.7.1.3. Cytochrome C Oxidase 1 Barcoding Assay
3.7.1.4. Phenotype Analysis
3.7.1.5. DNA Fingerprinting
3.7.1.6. DNA Profiling
3.8.2. Genetic Stability Testing
3.8.3. Sterility / Biosafety Testing
3..3.1. Mycoplasma Contamination Testing
3.6.3.2. Viral Contamination Testing
3.6.3.3. Other Sterility Testing Methods
3.7. Additional Cell Line Related Services
3.7.1. Cell Banking
3.7.1.1. Classification of Cell Banks
3.7.2. Process Development
3.7.2.1. Upstream Process Development
3.7.2.2. Downstream Process Development
3.7.3. cGMP Manufacturing
3.8. Applications of Cell Lines
3.9. Factors Affecting the Quality of Cell Lines
3.10. Need for Outsourcing Cell Line Related Operations
4. CELL LINE DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell Line Development Service Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Source of Cell Line and Expression System Offered
4.2.5. Analysis by Types of Services Offered
4.2.5.1. Integrated Cell Line Characterization
4.2.5.2. Biosimilar Cell Line Development
4.2.5.3. Genetically Modified Cell Line Development
4.2.6. Analysis by Gene Delivery Method Used
4.2.7. Analysis by Type of Gene Expression
4.2.8. Analysis by Availability of Serum-Free / Animal Component Free Culturing Capabilities
4.2.9. Analysis by Types of Cell Cultures
4.2.10. Analysis by Types of Cells
4.2.11. Analysis by Applications of Cell Lines
4.2.12. Analysis by Availability of Additional Cell Line Related Services
4.2.13. Analysis by Type of Cell Bank(s) Developed
4.2.14. Geographical Presence Analysis of Companies (offering multiple cell lines) by Sources of Cell Lines and Company Size
4.2.14.1. North America
4.2.14.2. Europe
4.2.14.3. Asia-Pacific
4.2.15. Geographical Presence Analysis of Companies (offering a single cell line) by Source of Cell Line and Company Size
4.2.16. Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Additional Cell Line Related Services
4.2.17. Heat Map Analysis: Distribution by Location of Headquarters and Combinations of Sources of Cell Lines Offered
4.2.18. Information on Protein Yield from Cell Lines
5. CELL LINE DEVELOPMENT SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.3.1. Company Competitiveness Analysis: Cell Line Development Service Providers in North America
5.3.2. Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
5.3.3. Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific
5.4. Summary
6. COMPANY PROFILES: CELL LINE DEVELOPMENT SERVICE PROVIDERS
6.1. Chapter Overview
6.2. Cell Line Development Service Providers: North America
6.2.1. Creative Biogene
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook
6.2.3. Hyprocell
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Recent Developments and Future Outlook
6.2.5. Thermo Fisher Scientific
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.3. Cell Line Development Service Providers: Europe
6.3.1. FUJIFILM Diosynth Biotechnologies
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Lonza
6.3.2.1. Company Overview
6.3.2.2. Financial Information
6.3.2.3. Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. ProBioGen
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Polpharma Biologics
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook
6.3.5. Selexis
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.4. Cell Line Development Service Providers: Asia-Pacific
6.4.1. Detai Bio-Tech
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. WuXi Biologics
6.4.2.1. Company Overview
6.4.2.2. Financial Information
6.4.2.3. Service Portfolio
6.4.2.4. Recent Developments and Future Outlook
7. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Cell Line Characterization Service Providers: Overall Market Landscape
7.2.1. Cell Line Characterization Service Providers: Industry Players
7.2.1.1. Analysis by Year of Establishment
7.2.1.2. Analysis by Company Size
7.2.1.3. Analysis by Location of Headquarters
7.2.1.4. Analysis by Types of Cells Handled
7.2.1.5. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.1.6. Analysis by Type of Cell Line Identity / Stability Testing Service(s) Offered
7.2.1.7. Analysis by Type of Sterility / Biosafety Testing Service(s) Offered
7.2.1.8. Analysis by Availability of Additional Cell Line Related Services
7.2.1.9. Geographical Presence Analysis of Companies (offering multiple cell lines) by Location of Headquarters
7.2.2. Cell Line Characterization Service Providers: Non-Industry Players
7.2.2.1. Analysis by Service Location
7.2.2.2. Analysis by Types of Cells Handled
7.2.2.3. Analysis by Type of Cell Line Characterization Service(s) Offered
7.2.2.4. Analysis by Number of STR Loci Amplified
7.2.2.5. Analysis by Type of Genotyping Kit(s) Used
8. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.3.1. Company Competitiveness Analysis: Cell Line Characterization Service Providers in North America
8.3.2. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Europe
8.3.3. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Asia-Pacific
8.4. Summary
9. COMPANY PROFILES: CELL LINE CHARACTERIZATION SERVICE PROVIDERS
9.1. Chapter Overview
9.2. Cell Line Characterization Service Providers: North America
9.2.1. BioReliance
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Recent Developments and Future Outlook
9.2.2. Charles River Laboratories
9.2.2.1. Company Overview
9.2.2.3. Financial Information
9.2.2.2. Service Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Molecular Diagnostic Services
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Recent Developments and Future Outlook
9.3. Cell Line Characterization Service Providers: Europe
9.3.1. Eurofins BioPharma Product Testing
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Recent Developments and Future Outlook
9.3.2. Sartorius Stedim Biotech
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Recent Developments and Future Outlook
9.3.3. SGS
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Recent Developments and Future Outlook
9.4. Cell Line Characterization Service Providers: Asia-Pacific
9.4.1. LivoGen Pharmed
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Recent Developments and Future Outlook
9.4.2. TFBS Bioscience
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Recent Developments and Future Outlook
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell Line Development and Characterization Service Providers: List of Partnerships and Collaborations
10.4. Analysis by Year of Partnership
10.5. Analysis by Type of Partnership
10.6. Analysis by Types of Cells Involved
10.7. Analysis by Type of Technology Platform Used
10.8. Analysis by Type of Indication
10.9. Analysis by Year of Partnership and Type of Partner
10.10. Analysis by Type of Partnership and Type of Partner
10.11. Most Active Players: Analysis by Number of Partnerships
10.12. Regional Analysis
10.13. Intercontinental and Intracontinental Agreements
11. CELL LINE REPOSITORIES
11.1. Chapter Overview
11.2. American Type Culture Collection (ATCC)
11.2.1. Overview
11.2.2. Service Portfolio
11.3. European Collection of Authenticated Cell Cultures (ECACC)
11.3.1. Overview
11.3.2. Service Portfolio
11.4. Leibniz Institute DSMZ
11.4.1. Overview
11.4.2. Service Portfolio
11.5. Coriell Institute for Medical Research
11.5.1. Overview
11.5.1.1. Service Portfolio
12. REGULATORY RECOMMENDATIONS AND GUIDELINES
12.1. Chapter Overview
12.2. History of Cell Line Authentication
12.3. Cell Line Authentication: Prominent Regulatory Authorities
12.3.1. Role of American Type Culture Collection (ATCC)
12.3.2. Role of International Cell Line Authentication Committee (ICLAC)
12.3.3. Role of Global Biological Standards Institute (GBSI)
12.4. Guidelines Issued by International Regulatory Agencies for Cell Line Characterization
12.4.1. World Health Organization (WHO)
12.4.2. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
12.5. Regulatory Guidelines for Cell Line Characterization in the US
12.6. Regulatory Guidelines for Cell Line Characterization in Europe
12.7. Regulatory Guidelines for Cell Line Characterization in Japan
13. CELL LINE DEVELOPMENT SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Line Development Services Market, 2020-2030
13.4. Cell Line Development Services Market, 2020-2030: Distribution by Sources of Cell Lines and Expression Systems Used
13.5. Cell Line Development Services Market, 2020-2030: Distribution by Applications
13.6. Cell Line Development Services Market, 2020-2030: Distribution by Company Size
13.7. Cell Line Development Services Market, 2020-2030: Distribution by Geography
13.7.1. Cell Line Development Services Market in North America, 2020-2030
13.7.1.1. Cell Line Development Services Market in North America, 2020-2030: Share of Small-sized Companies
13.7.1.2. Cell Line Development Services Market in North America, 2020-2030: Share of Mid-sized Companies
13.7.1.3. Cell Line Development Services Market in North America, 2020-2030: Share of Large Companies
13.7.1.4. Cell Line Development Services Market in North America, 2020-2030: Share of Research and Development Operations
13.7.1.5. Cell Line Development Services Market in North America, 2020-2030: Share of Drug Development Operations
13.7.2. Cell Line Development Services Market in Europe, 2020-2030
13.7.2.1. Cell Line Development Services Market in Europe, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Europe, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Europe, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Europe, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Europe, 2020-2030: Share of Drug Development Operations
13.7.2. Cell Line Development Services Market in Asia, 2020-2030
13.7.2.1. Cell Line Development Services Market in Asia, 2020-2030: Share of Small-sized Companies
13.7.2.2. Cell Line Development Services Market in Asia, 2020-2030: Share of Mid-sized Companies
13.7.2.3. Cell Line Development Services Market in Asia, 2020-2030: Share of Large Companies
13.7.2.4. Cell Line Development Services Market in Asia, 2020-2030: Share of Research and Development Operations
13.7.2.5. Cell Line Development Services Market in Asia, 2020-2030: Share of Drug Development Operations
13.7.3. Cell Line Development Services Market in Oceania, 2020-2030
13.7.3.1. Cell Line Development Services Market in Oceania, 2020-2030: Share of Small-sized Companies
13.7.3.2. Cell Line Development Services Market in Oceania, 2020-2030: Share of Mid-sized Companies
13.7.3.3. Cell Line Development Services Market in Oceania, 2020-2030: Share of Large Companies
13.7.3.4. Cell Line Development Services Market in Oceania, 2020-2030: Share of Research and Development Operations
13.7.3.5. Cell Line Development Services Market in Oceania, 2020-2030: Share of Drug Development Operations
13.7.4. Cell Line Development Services Market in Rest of the World, 2020-2030
13.7.4.1. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Small-sized Companies
13.7.4.2. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Mid-sized Companies
13.7.4.3. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Large Companies
13.7.4.4. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Research and Development Operations
13.7.4.5. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Drug Development Operations
14. CELL LINE CHARACTERIZATION SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Overall Cell Line Characterization Services Market, 2020-2030
14.4. Cell Line Characterization Services Market, 2020-2030: Distribution by Sources of Cell Lines
14.5. Cell Line Characterization Services Market, 2020-2030: Distribution by Geography
14.6. Cell Line Characterization Services Market, 2020-2030: Distribution by Type of Industry
14.7. Cell Line Characterization Services Market, 2020-2030: Distribution by Stage of Development of Biologics
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Northway Biotech
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Virgilijus Kupinas, Marketing and Business Development Coordinator (Q4 2020)
15.3. QuaCell Biotechnology
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Fai Poon, Founder and President (Q3 2020)
15.4. Polpharma Biologics
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Louis Boon, Chief Scientific Officer (Q3 2020)
15.5. LakePharma
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Fan Chen, Former Vice President BioProcessing (Q3 2017)
15.6. ARTES Biotechnology
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Michael Pointek, Founder and Managing Director (Q3 2017)
15.7. ImmunoPrecise Antibodies
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Nienke Smits, Client Relations Manager (Q3 2017)
15.8. Bioceros (acquired by Polpharma Biologics)
15.8.1. Interview Transcript: Oscar Hoogteijling, Former Global Business Development Manager (Q3 2017)
16. SURVEY ANALYSIS
16.1. Chapter Overview
16.2. Overview of Respondents
16.3. Designation of Respondents
16.4. Survey Insights
16.4.1. Type of Cell Line Offered
16.4.2. Source of Cell Line
16.4.3. Applications of Cell Lines
16.4.4. Cell Line Characterization Services
16.4.5. Cell Banking Services
16.4.6. Biologics Manufacturing Services
16.4.7. Fill / Finish Services
17. CONCLUDING REMARKS
17.1. Chapter Overview
17.2. Key Takeaways
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Primary and Secondary Cell Cultures
Figure 3.2 Initiation of Cell Cultures
Figure 3.3 Recombinant Cell Line Development: Process Workflow
Figure 3.4 Hybridoma Cell Line Development: Process Workflow
Figure 3.5 Sources of Non-Mammalian Cell Lines
Figure 3.6 Testing Methods for Cell Line Characterization
Figure 3.7 Karyotype Preparation: Process Workflow
Figure 3.8 DNA Hybridization: Process Workflow
Figure 3.9 DNA Fingerprinting: Process Workflow
Figure 3.10 DNA Fingerprinting: Process Workflow
Figure 3.11 Master and Working Cell Banks Production: Process Workflow
Figure 3.12 Cell Line Development in Overall Biomanufacturing Process
Figure 3.13 Applications of Cell Lines
Figure 3.14 Factors Affecting the Quality of Cell Lines
Figure 3.15 Advantages and Risks Associated with Outsourcing of Cell Line Related Operations
Figure 4.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Figure 4.2 Cell Line Development Service Providers: Distribution by Company Size
Figure 4.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Figure 4.4 World Map Representation: Analysis by Geography
Figure 4.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
Figure 4.6 Cell Line Development Service Providers Offering Multiple Cell Lines in North America: Distribution by Sources of Cell Lines and Company Size
Figure 4.7 Cell Line Development Service Providers Multiple Cell Lines in Europe: Distribution by Sources of Cell Lines and Company Size
Figure 4.8 Cell Line Development Service Providers Offering Multiple Cell Lines in Asia-Pacific: Distribution by Sources of Cell Lines and Company Size
Figure 4.9 Cell Line Development Service Providers Offering Single Cell Line: Distribution by Sources of Cell Lines and Company Size
Figure 4.10 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Figure 4.11 Cell Line Development Service Providers: Distribution by Availability of Integrated Biosimilar Cell Line Development Service
Figure 4.12 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
Figure 4.13 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
Figure 4.14 Cell Line Development Service Providers: Distribution by Type of Gene Expression
Figure 4.15 Cell Line Development Service Providers: Distribution by Usage of Serum-free / Animal Component Free Media
Figure 4.16 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
Figure 4.17 Cell Line Development Service Providers: Distribution by Types of Cells Offered
Figure 4.18 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
Figure 4.19 Cell Line Development Service Providers: Distribution by Types of Additional Cell Line Related Services Offered
Figure 4.20 Cell Line Development Service Providers: Distribution by Type of Cell Bank(s)
Figure 4.21 Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Cell Line Related Services
Figure 4.22 Heat Map Analysis: Distribution by Location of Headquarters and Sources of Cell Lines Offered
Figure 5.1 Company Competitiveness: Cell Line Development Service Providers in North America
Figure 5.2 Company Competitiveness: Cell Line Development Service Providers in Europe
Figure 5.3 Company Competitiveness: Cell Line Development Service Providers in Asia-Pacific
Figure 5.4 Company Competitiveness: Top Cell Line Development Service Providers
Figure 6.1 Thermo Fisher Scientific: Annual Revenues, FY 2015-H1 2020 (EUR Billion)
Figure 6.2 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
Figure 6.3 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
Figure 7.1 Cell Line Characterization Service Providers: Overall Market Landscape
Figure 7.2 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
Figure 7.3 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
Figure 7.4 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 7.5 World Map Representation: Analysis by Geography
Figure 7.6 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
Figure 7.7 Cell Line Development Service Providers (Industry Players): Distribution of Companies Offering Multiple Cell Lines by Location of Headquarters
Figure 7.8 Cell Line Development Service Providers (Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Figure 7.9 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
Figure 7.10 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
Figure 7.11 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
Figure 7.12 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
Figure 7.13 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
Figure 7.14 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Figure 7.15 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit(s) Used
Figure 7.16 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
Figure 8.1 Company Competitiveness: Cell Line Characterization Service Providers in North America
Figure 8.2 Company Competitiveness: Cell Line Characterization Service Providers in Europe
Figure 8.3 Company Competitiveness: Cell Line Characterization Service Providers in Asia-Pacific
Figure 8.4 Company Competitiveness: Top Cell Line Characterization Service Providers
Figure 9.1 Charles River Laboratories: Annual Revenues, FY 2015-Q1-Q3 2020 (USD Million)
Figure 9.2 Sartorius Stedim Biotech, Annual Revenues, FY 2016-H1 2020 (EUR Million)
Figure 9.3 SGS: Annual Revenues, FY 2015-H1 2020 (CHF Million)
Figure 10.1 Partnerships and Collaborations: Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Product being Licensed
Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.7 Most Active Players: Distribution by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Regional Distribution
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.10 Most Popular Technology Platform: Distribution by Number of Partnerships
Figure 10.11 Partnerships and Collaborations: Distribution by Types of Cells Involved
Figure 10.12 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
Figure 11.1 ATCC: Service Portfolio
Figure 11.2 ECACC: Biological Material Collection
Figure 11.3 ECACC: Service Portfolio
Figure 11.4 Leibniz Institute DSMZ: Biological Material Collection
Figure 11.5 Coriell Institute of Medical Research: Operating Segments
Figure 11.6 Coriell Institute for Medical Research: Service Portfolio
Figure 12.1 ICH Q5A (R1) Guidelines: Cell Bank Qualification
Figure 12.2 ICH Q5D Guidelines: Cell Bank Characterization
Figure 12.3 FDA Guidelines: Cell Bank Qualification
Figure 12.4 USP 63: Mycoplasma Detection in Cell Banks
Figure 12.5 CFR 610.18: Recommendations for Testing of Cell Lines
Figure 12.6 CFR 113.52: Recommendations for Testing of Cell Banks
Figure 12.7 EP 2.6.7: Recommendations for Mycoplasma Testing of Cell Banks
Figure 12.8 JP: Recommendations for Mycoplasma Testing of Cell Banks
Figure 13.1 Global Cell Line Development Services Market: 2020-2030 (USD Million)
Figure 13.2 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
Figure 13.3. Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
Figure 13.4 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
Figure 13.5 Cell Line Development Services Market for Insect Cell Lines, 2020-2030 (USD Million)
Figure 13.6 Cell Line Development Services Market for Avian Cell Lines, 2020-2030 (USD Million)
Figure 13.7 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
Figure 13.8 Cell Line Development Services Market for Bioproduction, 2020-2030 (USD Million)
Figure 13.9 Cell Line Development Services Market for Research and Development Operations, 2020-2030 (USD Million)
Figure 13.10 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030 (USD Million)
Figure 13.11 Cell Line Development Services Market for Small Companies, 2020-2030 (USD Million)
Figure 13.12 Cell Line Development Services Market for Mid-sized Companies, 2020-2030 (USD Million)
Figure 13.13 Cell Line Development Services Market for Large Companies, 2020-2030 (USD Million)
Figure 13.14 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 13.15 Cell Line Development Services Market in North America, 2020-2030 (USD Million)
Figure 13.16 Cell Line Development Services Market in Europe, 2020-2030 (USD Million)
Figure 13.17 Cell Line Development Services Market in Asia, 2020-2030 (USD Million)
Figure 13.18 Cell Line Development Services Market in Oceania, 2020-2030 (USD Million)
Figure 13.19 Cell Line Development Services Market in the Rest of the World, 2020 (USD Million)
Figure 14.1 Global Cell Line Characterization Services Market, 2020-2030 (USD Million)
Figure 14.2 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030 (USD Million)
Figure 14.3 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
Figure 14.4 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
Figure 14.5 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
Figure 14.6 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030 (USD Million)
Figure 14.7 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
Figure 14.8 Cell Line Characterization Services Market for Bioproduction, 2020-2030 (USD Million)
Figure 14.9 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030 (USD Million)
Figure 14.10 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030 (USD Million)
Figure 14.11 Cell Line Characterization Services Market for Industry Players, 2020-2030 (USD Million)
Figure 14.12 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030 (USD Million)
Figure 14.13 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 14.14 Cell Line Characterization Services Market in the US, 2020-2030 (USD Million)
Figure 14.15 Cell Line Characterization Services Market in Canada, 2020-2030 (USD Million)
Figure 14.16 Cell Line Characterization Services Market in the UK, 2020-2030 (USD Million)
Figure 14.17 Cell Line Characterization Services Market in France, 2020-2030 (USD Million)
Figure 14.18 Cell Line Characterization Services Market in Germany, 2020-2030 (USD Million)
Figure 14.19 Cell Line Characterization Services Market in Spain, 2020-2030 (USD Million)
Figure 14.20 Cell Line Characterization Services Market in Italy, 2020-2030 (USD Million)
Figure 14.21 Cell Line Characterization Services Market in Rest of Europe, 2020-2030 (USD Million)
Figure 14.22 Cell Line Characterization Services Market in China, 2020-2030 (USD Million)
Figure 14.23 Cell Line Characterization Services Market in Japan, 2020-2030 (USD Million)
Figure 14.24 Cell Line Characterization Services Market in India, 2020-2030 (USD Million)
Figure 14.25 Cell Line Characterization Services Market in Latin America, 2020-2030 (USD Million)
Figure 14.26 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030 (USD Million)
Figure 14.27 Cell Line Characterization Services Market in the Rest of the World, 2020-2030 (USD Million)
Figure 16.1 Survey Analysis: Distribution by Location of Organization
Figure 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Figure 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 16.4 Survey Analysis: Distribution by Types of Cell Lines
Figure 16.5 Survey Analysis: Distribution by Sources of Cell Lines
Figure 16.6 Survey Analysis: Distribution by Applications of Cell Lines
Figure 16.7 Survey Analysis: Cell Line Characterization Services
Figure 16.8 Survey Analysis: Cell Banking Services
Figure 16.9 Survey Analysis: Biologics Manufacturing Services
Figure 16.10 Survey Analysis: Fill / Finish Services
Figure 17.1 Concluding Remarks: Current Market Landscape of Cell Line Development Services
Figure 17.2 Concluding Remarks: Current Market Landscape of Cell Line Characterization Services
Figure 17.3 Concluding Remarks: Geographical Distribution of Cell Line Development and Characterization Service Providers
Figure 17.4 Concluding Remarks: Partnerships and Collaborations
Figure 17.5 Concluding Remarks: Cell Line Development Services Market Sizing and Opportunity Analysis
Figure 17.6 Concluding Remarks: Cell Line Characterization Services Market Sizing and Opportunity Analysis
Table 3.1 Comparison between Finite and Continuous Cell Lines
Table 3.2 Popular Mammalian Cell Lines used in Biopharmaceutical Production
Table 3.3 Human Cell Lines and Therapeutic Protein Products
Table 3.4 Cell Lines and Viral Vaccine Products
Table 4.1 Cell Line Development Service Providers: List of Players
Table 4.2 Cell Line Development Service Providers: Information on Sources of Cell Lines and Expresion Systems Offered
Table 4.3 Cell Line Development Service Providers: Information on Technology and Service related Parameters
Table 4.4 Cell Line Development Service Providers: Information on Cell Line Development Process Related Parameters
Table 4.5 Cell Line Development Service Providers: Information on Types of Cells Offered and Applications of Cell Lines
Table 4.6 Cell Line Development Service Providers: Information on Additional Cell Line Related Services
Table 4.7 Cell Line Development Service Providers: Information on Yield / Amount of Protein Expressed from Cell Lines
Table 6.1 Cell Line Development Service Providers: List of Profiled Companies
Table 6.2 Creative Biogene: Company Snapshot
Table 6.3 Creative Biogene: Overview of Cell Line Development Services
Table 6.4 Creative Biogene: Recent Developments and Future Outlook
Table 6.5 Creative Biolabs: Company Snapshot
Table 6.6 Creative Biolabs: Overview of Cell Line Development Services
Table 6.7 Creative Biolabs: Recent Developments and Future Outlook
Table 6.8 Hyprocell: Company Snapshot
Table 6.9 Hyprocell: Overview of Cell Line Development Services
Table 6.10 Hyprocell: Recent Developments and Future Outlook
Table 6.11 LakePharma: Company Snapshot
Table 6.12 LakePharma: Overview of Cell Line Development Services
Table 6.13 LakePharma: Recent Developments and Future Outlook
Table 6.14 Thermo Fisher Scientific: Company Snapshot
Table 6.15 Thermo Fisher Scientific: Overview of Cell Line Development Services
Table 6.16 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.17 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.18 FUJIFILM Diosynth Biotechnologies: Overview of Cell Line Development Services
Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.20 Lonza: Company Snapshot
Table 6.21 Lonza: Overview of Cell Line Development Services
Table 6.22 Lonza: Recent Developments and Future Outlook
Table 6.23 ProBioGen: Company Snapshot
Table 6.24 ProBioGen: Overview of Cell Line Development Services
Table 6.25 ProBioGen: Recent Developments and Future Outlook
Table 6.26 Polpharma Biologics: Company Snapshot
Table 6.27 Polpharma Biologics: Overview of Cell Line Development Services
Table 6.28 Polpharma Biologics: Recent Developments and Future Outlook
Table 6.29 Selexis: Company Snapshot
Table 6.30 Selexis: Overview of Cell Line Development Services
Table 6.31 Selexis: Recent Developments and Future Outlook
Table 6.32 Detai Bio-Tech: Company Snapshot
Table 6.33 Detai Bio-Tech: Overview of Cell Line Development Services
Table 6.34 Detai Bio-Tech: Recent Developments and Future Outlook
Table 6.35 WuXi Biologics: Company Snapshot
Table 6.36 WuXi Biologics: Overview of Cell Line Development Services
Table 6.37 WuXi Biologics: Recent Developments and Future Outlook
Table 7.1 Cell Line Characterization Service Providers: List of Industry Players
Table 7.2 Cell Line Characterization Service Providers (Industry Players): Information of Types of Cells Handled
Table 7.3 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Characterization Service(s) Offered
Table 7.4 Cell Line Characterization Service Providers (Industry Players): Type of Cell Identity / Stability Testing Service(s) Offered
Table 7.5 Cell Line Characterization Service Providers (Industry Players): Type of Cell Sterility / Biosafety Testing Service(s) Offered
Table 7.6 Cell Line Characterization Service Providers (Industry Players): Information on Additional Cell Line Related Services
Table 7.7 Cell Line Characterization Service Providers (Industry Players): Information on Regulatory Accreditations / Certifications and Overall Turnaround Time
Table 7.8 Cell Line Characterization Service Providers: List of Non-Industry Players and Types of Cells Handled
Table 7.9 Cell Line Characterization Service Providers (Non-Industry Players): Information on Type of Cell Line Characterization Service(s) Offered
Table 7.10 Line Characterization Service Providers (Non-Industry Players): Information on Genotyping Testing Services Offered
Table 7.11 Cell Line Characterization Service Providers (Non-Industry Players): Information on Service Fee Charged and Overall Turnaround Time
Table 7.12 Cell Line Characterization Service Providers: List of Players Offering Primary Cell / Stem Cell Characterization
Table 9.1 Cell Line Characterization Service Providers: List of Profiled Companies
Table 9.2 BioReliance: Company Snapshot
Table 9.3 BioReliance: Overview of Cell Line Development Services
Table 9.4 BioReliance: Recent Developments and Future Outlook
Table 9.5 Charles River Laboratories: Company Snapshot
Table 9.7 Charles River Laboratories: Overview of Cell Line Development Services
Table 9.8 Charles River Laboratories: Recent Developments and Future Outlook
Table 9.9 Molecular Diagnostic Services: Company Snapshot
Table 9.10 Molecular Diagnostic Services: Overview of Cell Line Development Services
Table 9.11 Molecular Diagnostic Services: Recent Developments and Future Outlook
Table 9.12 Eurofins BioPharma Product Testing: Company Snapshot
Table 9.13 Eurofins BioPharma Product Testing: Overview of Cell Line Development Services
Table 9.14 Eurofins BioPharma Product Testing: Recent Developments and Future Outlook
Table 9.15 Sartorius Stedim Biotech: Company Snapshot
Table 9.16 Sartorius Stedim Biotech: Financial Information
Table 9.17 Sartorius Stedim Biotech: Overview of Cell Line Development Services
Table 9.18 Sartorius Stedim Biotech: Recent Developments and Future Outlook
Table 9.19 SGS: Company Snapshot
Table 9.20 SGS: Overview of Cell Line Development Services
Table 9.21 SGS: Recent Developments and Future Outlook
Table 9.22 LivoGen Pharmed: Company Snapshot
Table 9.23 LivoGen Pharmed: Overview of Cell Line Development Services
Table 9.24 LivoGen Pharmed: Recent Developments and Future Outlook
Table 9.25 TFBS Bioscience: Company Snapshot
Table 9.26 TFBS Bioscience: Overview of Cell Line Development Services
Table 9.27 TFBS Bioscience: Recent Developments and Future Outlook
Table 10.1 Cell Line Development and Service Providers: List of Partnerships and Collaborations
Table 11.1 ATCC: Overview
Table 11.2 ECACC: Overview
Table 11.3 DSMZ: Overview
Table 12.1 WHO Recommendations: Cell Bank Characterization
Table 12.2 Regulatory Documents for Cell Line Characterization in the US
Table 12.3 USP 1050: Virus Testing in Cell Banks
Table 12.4 EP 5.2.3: Testing in Cell Banks
Table 15.1 Company Snapshot: Laragen
Table 15.2 Company Snapshot: QuaCell biotechnology
Table 15.3 Company Snapshot: Polpharma Biologics
Table 15.4 Company Snapshot: LakePharma
Table 15.5 Company Snapshot: ARTES Biotechnology
Table 15.6 Company Snapshot: ImmunoPrecise Antibodies
Table 16.1 Survey Analysis: Distribution by Location of Organization
Table 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
Table 16.4 Survey Analysis: Distribution by Types of Cell Lines
Table 16.5 Survey Analysis: Distribution by Sources of Cell Lines
Table 16.6 Survey Analysis: Distribution by Applications of Cell Lines
Table 16.7 Survey Analysis: Cell Line Characterization Services
Table 16.8 Survey Analysis: Cell Banking Services
Table 16.9 Survey Analysis: Biologics Manufacturing Services
Table 16.10 Survey Analysis: Fill / Finish Services
Table 18.1 Cell Line Development Service Providers: Distribution by Year of Establishment
Table 18.2 Cell Line Development Service Providers: Distribution by Company Size
Table 18.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
Table 18.4 Cell Line Development Service Providers: Distribution by Geography
Table 18.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
Table 18.6 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
Table 18.7 Cell Line Development Service Providers: Distribution by Availability of Biosimilar Cell Line Development Service
Table 18.8 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
Table 18.9 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
Table 18.10 Cell Line Development Service Providers: Distribution by Type of Gene Expression
Table 18.11 Cell Line Development Service Providers: Distribution by Availability of Serum-Free / Animal Component Free Culturing Capability
Table 18.12 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
Table 18.13 Cell Line Development Service Providers: Distribution by Types of Cells Offered
Table 18.14 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
Table 18.15 Cell Line Development Services Providers: Distribution by Types of Additional Cell Line Related Services Offered
Table 18.16 Cell Line Development Services Providers: Distribution by Type of Cell Bank(s) Developed
Table 18.17 Thermo Fisher Scientific: Annual Revenues, FY2015-H1 2020 (USD Billion)
Table 18.18 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
Table 18.19 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
Table 18.20 Cell Line Characterization Service Providers: Overall Market Landscape
Table 18.21 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
Table 18.22 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
Table 18.23 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
Table 18.24 Cell Line Characterization Service Providers: Distribution by Geography
Table 18.25 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
Table 18.26 Cell Line Development Service Providers (Industry Players): Analysis by Type of Cell Line Characterization Service(s) Offered
Table 18.27 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
Table 18.28 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
Table 18.29 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
Table 18.30 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
Table 18.31 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
Table 18.32 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
Table 18.33 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit Used
Table 18.34 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
Table 18.35 Charles River Laboratories: Annual Revenues, 2015-Q3 2020 (USD Billion)
Table 18.36 Sartorius Stedim Biotech: Annual Revenues, 2015-Q3 2020 (EUR Billion)
Table 18.37 SGS: Annual Revenues, 2015-H1 2020 (CHF Billion)
Table 18.38 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Table 18.41 Partnerships and Collaborations: Distribution by Type of Product being Licensed
Table 18.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 18.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.44 Most Active Players: Distribution by Number of Partnerships
Table 18.45 Partnerships and Collaborations: Regional Distribution
Table 18.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 18.47 Most Popular Technology Platforms: Distribution by Number of Partnerships
Table 18.48 Partnerships and Collaborations: Distribution by Types of Cells Involved
Table 18.49 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
Table 18.50 Global Cell Line Development Services Market: 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.51 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.52 Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.53 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.54 Cell Line Development Services Market for Insect Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.55 Cell Line Development Services Market for Avian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.56 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.57 Cell Line Development Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.58 Cell Line Development Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.59 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030: Base Scenario (USD Million)
Table 18.60 Cell Line Development Services Market for Small-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.61 Cell Line Development Services Market for Mid-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.62 Cell Line Development Services Market for Large Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.63 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
Table 18.64 Cell Line Development Services Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.65 Cell Line Development Services Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.66 Cell Line Development Services Market in Asia, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.67 Cell Line Development Services Market in Oceania, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.68 Cell Line Development Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.69 Global Cell Line Characterization Services Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.70 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030: Base Scenario (USD Million)
Table 18.71 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.72 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.73 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.74 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
Table 18.75 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
Table 18.76 Cell Line Characterization Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.77 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.78 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030: Base Scenario (USD Million)
Table 18.79 Cell Line Characterization Services Market for Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.80 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.81 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
Table 18.82 Cell Line Characterization Services Market in the US, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.83 Cell Line Characterization Services Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.84 Cell Line Characterization Services Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.85 Cell Line Characterization Services Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.86 Cell Line Characterization Services Market in the Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.87 Cell Line Characterization Services Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.88 Cell Line Characterization Services Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.89 Cell Line Characterization Services Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.90 Cell Line Characterization Services Market in China, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.91 Cell Line Characterization Services Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.92 Cell Line Characterization Services Market in India, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.93 Cell Line Characterization Services Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.94 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.95 Cell Line Characterization Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.96 Survey Analysis: Distribution by Location of Organization
Table 18.97 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 18.98 Survey Analysis: Distribution by Seniority Level of Respondents
Table 18.99 Survey Analysis: Distribution by Type of Cell Lines
Table 18.100 Survey Analysis: Distribution by Source of Cell Lines
Table 18.101 Survey Analysis: Distribution by Applications of Cell Lines
Table 18.102 Survey Analysis: Cell Line Characterization Services
Table 18.103 Survey Analysis: Cell Banking Services
Table 18.104 Survey Analysis: Biologics Manufacturing Services
Table 18.105 Survey Analysis: Fill / Finish Services
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES